About 9,809 shares traded. VEON Ltd (ADR) (NASDAQ:VIP) has 0.00% since June 19, 2016 and is. Therefore 75% are positive. Impinj had 5 analyst reports since February 17, 2017 according to SRatingsIntel. The stock boasts a consensus analyst "Buy" rating with the consensus recommendation standing at 2.20. Panmure Gordon maintained Hansard Global plc (LON:HSD) on Thursday, January 19 with "Buy" rating. The firm has "Hold" rating by Deutsche Bank given on Wednesday, July 22. As per Friday, January 13, the company rating was initiated by Morgan Stanley.
Shares of Clovis closed Friday at $59.97, with a consensus analyst price target of $71.17 and a 52-week range of $11.57 to $74.94. Clovis Oncology Inc (NDAQ:CLVS) has risen 282.71% since June 19, 2016 and is uptrending. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping analysts' consensus estimates of ($1.43) by $0.10. After $-1.33 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 3.01 % negative EPS growth.
Clovis Oncology, Inc.is a biopharmaceutical company which focuses on acquiring, developing and commercializing cancer treatments in the United States, Europe and other global markets. The company's market cap is $2.68 billion. Analyst Alethia Young argued that the company' ovarian cancer drug rucaparib could be a blockbuster product, and predicted success for a late-stage study underway known as Ariel3. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
The value of the investment in Clovis Oncology, Inc. went from $1,000 to $1,000 decreasing 0.0% quarter over quarter. Endurant Capital Management LP owned 0.07% of Clovis Oncology worth $2,028,000 at the end of the most recent quarter.
Clovis Oncology Inc (NASDAQ:CLVS) is soaring today, now up 50 percent at an even $90.00 - a $30.03 boost from Friday's closing price. Clovis Oncology, Inc. (CLVS) now trades with a market capitalization of $2.67 Billion. Rice Hall James & Assoc Ltd Llc holds 104,308 shares or 0.23% of its portfolio. Wellington Mngmt Limited Liability Partnership stated it has 0% in Clovis Oncology Inc (NASDAQ:CLVS). (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. 450,247 were reported by Jennison Assocs Ltd Liability Com. Oakbrook Invests Ltd Liability Corp reported 0.03% of its portfolio in ABIOMED, Inc.More news: Koepka's trip around the world leads to major title at home
EAM Investors LLC acquired a new stake in Clovis Oncology, Inc. Teachers Retirement System of The State of Kentucky bought a new stake in Clovis Oncology during the first quarter worth about $2,001,000. Equities research analysts predict that Clovis Oncology will post ($5.07) EPS for the current year. Chardan Capital Markets upgraded Clovis Oncology Inc (NASDAQ:CLVS) rating on Tuesday, December 20. Blackrock Advisors Ltd Limited Liability Company owns 60,785 shares. Pictet Asset Management Limited holds 195,285 shares or 0.03% of its portfolio.
Health care stocks were putting up strong gains to start the new week, with the NYSE Health Care Index adding more than 0.8% while shares of health care companies in the S&P 500 were up almost 1.1% as a group. Parametric Port Associates Llc accumulated 0% or 25,221 shares.
Since March 15, 2017, it had 0 insider buys, and 3 sales for $528,600 activity.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Thursday, June 15th.
Ultra Clean Holdings, Inc.is engaged in the design, engineering and manufacture of production tools, modules and subsystems the semiconductor capital equipment industry.